Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312728 | 0.86 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15267699 | 0.85 | KMT2A (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12807727 | 0.84 | GAA (0.61) | KMT2AATMSMN1; SMN2HPGDRAB9A | |
| SCHEMBL826066 | 0.84 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4787002 | 0.82 | KMT2A (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8667875 | 0.82 | KMT2A (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9843050 | 0.81 | TP53 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13381412 | 0.81 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8324087 | 0.81 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1031451 | 0.81 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716344-B | 2- ((2-acetamidophenyl) amino) acetamido compound and preparation method and application thereof | 湖南科技大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-114409657-B | 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof | 湖南科技大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-114716344-A | 2- ((2-acetamidophenyl) amino) acetyl arylamine compound and preparation method and application thereof | 湖南科技大学 | 2022-07-08 | — | — | CN | disclosed |
| CN-114409657-A | 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof | 湖南科技大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| EP-1689714-A2 | THERAPEUTIC USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054198-A2 | THERAPEUTICS USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105810-A1 | THERAPEUTICS | RYR1, ATP2A1, CACNA1E | HDAC3 761/4885HDAC4 1157/4885HDAC1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.